Literature DB >> 15385721

[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].

Sung Chul Park1, Hoon Jai Chun, Sung Woo Jung, Bora Keum, Woo Sik Han, Rok Son Choung, Yong Sik Kim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Sang Woo Lee, Jai Hyun Choi, Chang Duck Kim, Ho Sang Ryu, Jin Hai Hyun.   

Abstract

BACKGROUND/AIMS: As a second-line treatment for H. pylori eradication in the case of first-line OAC (omeprazole, amoxicillin, clarithromycin) treatment failure, a minimum of one-week OBMT quadruple therapy composed of omeprazole, bismuth, metronidazole, tetracycline has been recommended in European countries and one or two weeks in USA. In Korea, one-week OBMT quadruple therapy is recommended for the case of first-line OAC treatment failure. Because H. pylori eradication rate of one-week OBMT therapy in Korea is about 80%, the eradication rate of one week therapy is not satisfactory. We analyzed the effect of two-week second-line OBMT therapy.
METHODS: Between June 2002 and June 2003, 107 patients who were H. pylori positive (44 males and 63 females: mean age 51.8 years) after primary eradication therapy received two-week OBMT therapy. Four weeks after completion of therapy, 13C-urea breath test was performed to detect H. pylori.
RESULTS: After two weeks of OBMT therapy, eradication was achieved in 103 of 107 patients (96.3%) and in 68 of 71 peptic ulcer patients (95.8%).
CONCLUSIONS: Two-week OBMT therapy should be considered as a retreatment regimen with the eradication rate more than 90%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385721

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  3 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

2.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

3.  Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.